Profile data is unavailable for this security.
About the company
Everest Medicines Ltd is a biopharmaceutical company primarily engaged in the discovering, developing, manufacturing and commercializing transformative pharmaceutical products and vaccines. The Company has built a product pipeline across renal, anti-infective, and autoimmune diseases. The Company’s products portfolio includes Nefecon (TARPEYO) using in the renal therapeutic area, XERAVA (eravacycline) using in the treatment of infections caused by susceptible gram-positive, gram-negative and anaerobic pathogens including those multidrug resistant isolates and other products. The Company conducts its business in the domestic and overseas markets.
- Revenue in HKD (TTM)772.67m
- Net income in HKD-1.14bn
- Incorporated2017
- Employees665.00
- LocationEverest Medicines Ltd16/F., CITIC Pacific Plaza,1168 West Nanjing Road, JingAn DistrictSHANGHAI 200041ChinaCHN
- Websitehttps://www.everestmedicines.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sihuan Pharmaceutical Holdings Group Ltd | 2.08bn | -236.89m | 13.05bn | 2.67k | -- | 2.75 | -- | 6.28 | -0.0256 | -0.0256 | 0.2243 | 0.5172 | 0.1723 | 1.11 | 4.54 | 779,392.10 | -4.27 | -3.60 | -7.06 | -5.05 | 65.32 | 73.13 | -24.80 | -19.74 | 1.57 | -4.07 | 0.1489 | -- | 2.18 | -7.96 | -301.10 | -- | -20.58 | 3.60 |
| Luye Pharma Group Ltd | 6.63bn | 515.95m | 14.67bn | 5.15k | 28.44 | 0.9479 | 9.35 | 2.21 | 0.1372 | 0.1372 | 1.76 | 4.11 | 0.22 | 2.32 | 2.78 | 1,286,888.00 | 2.34 | 1.98 | 3.84 | 3.16 | 66.72 | 68.37 | 10.64 | 8.04 | 1.15 | 3.01 | 0.4001 | 0.00 | -1.33 | -0.9503 | -11.40 | -19.50 | -10.95 | -- |
| Yichang Hec Changjiang Pharmactcl Co Ltd | 4.07bn | 527.79m | 15.35bn | 4.86k | 29.08 | 1.65 | 15.97 | 3.77 | 0.5998 | 0.5998 | 4.63 | 10.57 | 0.2959 | 1.76 | 1.78 | 837,588.60 | 3.84 | 4.72 | 5.36 | 6.95 | 75.03 | 76.98 | 12.96 | 15.49 | 1.54 | 43.06 | 0.208 | 3.14 | -40.84 | -9.76 | -75.78 | -24.12 | -6.71 | -- |
| Everest Medicines Ltd | 772.67m | -1.14bn | 23.81bn | 665.00 | -- | 5.29 | -- | 30.81 | -3.55 | -3.55 | 2.41 | 13.73 | 0.1317 | 10.89 | 3.42 | 1,161,909.00 | -19.41 | -29.28 | -21.61 | -31.67 | 74.56 | -- | -147.36 | -1,040.86 | 2.52 | -- | 0.1238 | -- | 461.16 | -- | -23.32 | -- | 16.96 | -- |
| HUTCHMED (China) Ltd | 4.95bn | 296.15m | 23.98bn | 1.81k | 81.04 | 4.02 | 60.49 | 4.85 | 0.3393 | 0.3393 | 5.67 | 6.84 | 0.4935 | 6.93 | 4.53 | 2,731,509.00 | 2.99 | -9.55 | 4.36 | -13.77 | 44.64 | 39.84 | 6.06 | -20.32 | 2.70 | -- | 0.1042 | -- | -24.80 | 25.20 | -62.56 | -- | 15.93 | -- |
| The United Laboratories Intl. Hldgs Ltd. | 15.04bn | 2.91bn | 27.95bn | 17.00k | 9.61 | 1.78 | 7.81 | 1.86 | 1.60 | 1.60 | 8.28 | 8.66 | 0.5874 | 3.29 | 5.78 | 884,928.00 | 11.35 | 9.37 | 16.93 | 14.54 | 44.21 | 44.33 | 19.32 | 15.06 | 1.55 | -- | 0.1794 | 26.01 | 0.1387 | 10.39 | -1.54 | 32.89 | 37.25 | 45.96 |
| Duality Biotherapeutics Inc | -100.00bn | -100.00bn | 28.91bn | 170.00 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 8.66 | -- | -193.82 | -- | -- | -- |
| Simcere Pharmaceutical Group Ltd | 7.25bn | 801.63m | 29.55bn | 6.58k | 37.65 | 3.84 | 25.24 | 4.07 | 0.3172 | 0.3172 | 2.88 | 3.11 | 0.5934 | 2.17 | 2.48 | 1,101,887.00 | 6.56 | 8.74 | 8.65 | 12.42 | 80.25 | 78.53 | 11.05 | 15.60 | 1.79 | 3.60 | 0.1461 | 44.12 | 0.4148 | 5.67 | 2.57 | -6.09 | 8.48 | -- |
| Zai Lab Ltd | 3.28bn | -1.98bn | 32.05bn | 1.87k | -- | 4.91 | -- | 9.76 | -1.96 | -1.96 | 3.23 | 5.87 | 0.387 | 3.35 | 6.11 | -- | -23.32 | -33.80 | -30.56 | -39.12 | 63.62 | 64.07 | -60.26 | -186.77 | 3.09 | -- | 0.1762 | -- | 49.59 | 98.38 | 23.17 | -- | 32.19 | -- |
| China Medical System Holdings Ltd | 8.17bn | 1.77bn | 32.45bn | 6.14k | 18.24 | 1.82 | 15.85 | 3.97 | 0.7292 | 0.7292 | 3.36 | 7.31 | 0.4175 | 2.91 | 6.31 | 1,329,826.00 | 9.02 | 16.35 | 10.05 | 18.70 | 72.60 | 75.03 | 21.60 | 32.20 | 5.24 | -- | 0.0499 | 40.16 | -6.79 | 4.22 | -32.54 | -3.75 | 6.01 | -2.60 |
| China Resources Pharmaceutical Group Ltd | 281.74bn | 3.66bn | 33.74bn | 72.70k | 9.21 | 0.6396 | 2.62 | 0.1198 | 0.5832 | 0.5832 | 44.84 | 8.40 | 1.02 | 6.30 | 3.45 | 3,875,314.00 | 3.33 | 3.14 | 11.90 | 11.78 | 15.79 | 15.59 | 3.26 | 3.02 | 1.13 | 11.24 | 0.413 | 22.38 | 5.30 | 7.41 | -13.06 | 2.95 | 12.42 | 7.30 |
| Shanghai Henlius Biotech Inc | 6.26bn | 897.09m | 34.51bn | 3.52k | 38.47 | 10.47 | 26.41 | 5.51 | 1.65 | 1.65 | 11.52 | 6.06 | 0.5585 | 2.07 | 7.02 | 1,780,657.00 | 8.00 | -3.21 | 15.78 | -5.76 | 73.10 | 72.50 | 14.33 | -7.87 | 0.3544 | 10.04 | 0.5476 | -- | 6.11 | 128.98 | 50.26 | -- | 10.83 | -- |
| Grand Pharmaceutical Group Ltd | 11.64bn | 2.47bn | 34.89bn | 11.99k | 13.95 | 2.09 | 11.75 | 3.00 | 0.7046 | 0.7046 | 3.33 | 4.70 | 0.4902 | 3.56 | 11.01 | 971,460.10 | 10.38 | 10.40 | 14.08 | 14.24 | 57.86 | 61.04 | 21.18 | 22.80 | 1.01 | -- | 0.212 | 29.12 | 10.59 | 12.06 | 31.30 | 16.49 | 0.7398 | 22.05 |
Data as of Jul 18 2025. Currency figures normalised to Everest Medicines Ltd's reporting currency: Hong Kong Dollar HKD
5.25%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| The Vanguard Group, Inc.as of 02 Jul 2025 | 3.85m | 1.18% |
| GF Fund Management Co., Ltd.as of 31 Dec 2024 | 3.15m | 0.97% |
| BlackRock Fund Advisorsas of 03 Jul 2025 | 2.38m | 0.73% |
| Ping An Fund Management Co., Ltd.as of 31 Dec 2024 | 2.19m | 0.67% |
| China Asset Management Co., Ltd.as of 31 Dec 2024 | 1.60m | 0.49% |
| Bosera Asset Management Co., Ltd.as of 31 Dec 2024 | 1.57m | 0.48% |
| BlackRock Advisors (UK) Ltd.as of 04 Jul 2025 | 827.50k | 0.25% |
| E Fund Asset Management Co. Ltd.as of 31 Dec 2024 | 785.00k | 0.24% |
| SSgA Funds Management, Inc.as of 02 Jul 2025 | 417.50k | 0.13% |
| Dimensional Fund Advisors LPas of 04 Jul 2025 | 389.50k | 0.12% |
More ▼
Data from 31 Dec 2024 - 10 Jul 2025Source: FactSet Research Systems Inc.
